Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee

CONCLUSIONS: Close attention to incorporating HRQL and PROM's is critical to interpret the results of ovarian cancer clinical trials of maintenance therapies. There should be a consistent approach to assessing and reporting patient centered benefits across all GCIG trials to enable cross trial comparisons which can be used to inform practice.PMID:33612336 | DOI:10.1016/j.ygyno.2021.02.018

Source: Gynecologic Oncology - February 22, 2021 Category: Cancer & Oncology Authors: Jean-Emmanuel Kurtz Val Gebski Vladyslav Sukhin Mark Carey Iwa Kong Rosalind M Glasspool Jonathan S Berek Mariana de Paiva Batista Marcia Hall Jae-Weon Kim Effi Yeoshoua Noriko Fujiwara Byung-Ho Nam Sandra Polleis Jung-Yun Lee Aleksandra Strojna Laura Far Source Type: research